AMRX vs. AMPH, DCPH, RCKT, ZLAB, ARVN, KROS, CPRX, AGIO, GERN, and VERA
Should you be buying Amneal Pharmaceuticals stock or one of its competitors? The main competitors of Amneal Pharmaceuticals include Amphastar Pharmaceuticals (AMPH), Deciphera Pharmaceuticals (DCPH), Rocket Pharmaceuticals (RCKT), Zai Lab (ZLAB), Arvinas (ARVN), Keros Therapeutics (KROS), Catalyst Pharmaceuticals (CPRX), Agios Pharmaceuticals (AGIO), Geron (GERN), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical preparations" industry.
Amphastar Pharmaceuticals (NASDAQ:AMPH) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, community ranking, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.
Amphastar Pharmaceuticals has higher earnings, but lower revenue than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Amphastar Pharmaceuticals has a net margin of 22.88% compared to Amphastar Pharmaceuticals' net margin of -6.76%. Amphastar Pharmaceuticals' return on equity of 234.06% beat Amneal Pharmaceuticals' return on equity.
In the previous week, Amphastar Pharmaceuticals had 2 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 6 mentions for Amphastar Pharmaceuticals and 4 mentions for Amneal Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 0.74 beat Amneal Pharmaceuticals' score of 0.56 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.
Amphastar Pharmaceuticals has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.
Amphastar Pharmaceuticals received 377 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Amneal Pharmaceuticals an outperform vote while only 66.78% of users gave Amphastar Pharmaceuticals an outperform vote.
Amphastar Pharmaceuticals presently has a consensus price target of $66.00, indicating a potential upside of 51.79%. Amneal Pharmaceuticals has a consensus price target of $8.25, indicating a potential upside of 20.97%. Given Amneal Pharmaceuticals' higher probable upside, analysts plainly believe Amphastar Pharmaceuticals is more favorable than Amneal Pharmaceuticals.
65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are held by insiders. Comparatively, 26.6% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Amphastar Pharmaceuticals beats Amneal Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Amneal Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amneal Pharmaceuticals Competitors List
Related Companies and Tools
